Reduction of Psoriasis in a Patient under Network Spinal Analysis™ Care: A Case Report
Madeline Behrendt, D.C.

Journal of Vertebral Subluxation Research Volume 2, Number 4, Dec 199
p.196-200

Abstract: - This case report describes the progress of a 52 year old male with chronic psoriasis, first diagnosed in April of 1992. After the condition exacerbated over a five year period, he was placed on 12.5mg/week methtrexate, and oral immunosuppressant medication in October of 1997. After commencing the medication, the condition reduced from 65 body coverage, with flares of 15-20%, to a body coverage of 5%. Following a cessation of the oral medication in February, 1998, the condition recurred at the previous uncontrolled level within one month. The patient was again placed on 12.5mg/week methotrexate, and subsequently the condition was reduced to 5% body coverage. The patient’s dose was reduced to 10mg/week, and later to 7.5mg/week with the psoriasis remaining at 5% coverage. On 5/18/98, the patient commenced regular NSA care. He reported a reduction in the psoriasis condition on 6/3/98, and was taken off oral medication on 6/25/98. The reduction continued, and the patient was advised by his medical physician on 7/01/98 to continue the cessation of oral medication. As of 9/30/98 the psoriasis had decreased to .5% to 1.0% of coverage, and prior plans to initiate ultraviolet-A-therapy were canceled. As of 11/98, a five month period since cessation of methotrexate, the patient has remained under regular NSA care, with no recurrence of psoriasis body coverage greater than 1%, the only medication being a topical ointment. This is contrasted to the recurrence after one month following the patient’s first cessation of methotrexate, and prior to NSA care. The possible role of NSA care in the reduction of the patient’s psoriasis, and other health benefits is discussed.